Related Experiment Video
Updated: Jun 12, 2026
05:59
High-Throughput Small Molecule Drug Screening For Age-Related Sleep Disorders Using Drosophila melanogaster
Published on: October 20, 2023
Agomelatine, the first melatonergic antidepressant: discovery, characterization and development
Christian de Bodinat1, Béatrice Guardiola-Lemaitre, Elisabeth Mocaër
1Institut de Recherches Internationales Servier, 6 Place des Pléiades, 92415 Courbevoie, Cedex, France.
Nature Reviews. Drug Discovery
|June 26, 2010
Summary
Agomelatine offers a novel approach to treating major depression by targeting melatonergic receptors and 5-HT2C receptors, moving beyond traditional monoaminergic antidepressants. This non-monoaminergic antidepressant was approved in Europe in 2009.
Area of Science:
- Neuroscience
- Pharmacology
- Psychiatry
Background:
- Major depression management remains suboptimal, with current antidepressants relying solely on monoaminergic mechanisms.
- Circadian rhythm disruptions are common in depression, highlighting the role of melatonin.
- Novel non-monoaminergic antidepressant strategies are of significant interest.
Purpose of the Study:
- To describe the discovery and development of agomelatine.
- To highlight agomelatine's unique dual mechanism of action: melatonergic agonism and 5-HT2C antagonism.
Main Methods:
- Comprehensive pharmacological evaluation of agomelatine.
- Extensive clinical trials to assess efficacy and safety.
Main Results:
- Agomelatine demonstrated a novel non-monoaminergic mechanism of action.
- Successful completion of clinical trials leading to regulatory approval.
Conclusions:
- Agomelatine represents the first approved antidepressant with a non-monoaminergic mechanism.
- This development offers a new therapeutic option for major depression management.
Related Concept Videos
01:17Sedatives and Hypnotics Drugs: Miscellaneous Agents
Sedatives and hypnotics encompass a wide range of substances, each with its unique mechanism of action, uses, and potential adverse effects.
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...
01:23Antidepressant Drugs: MAOIs and Other Agents
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
01:19Management of Insomnia
The sleep cycle, an integral part of human health, consists of several stages with distinct characteristics and functions. It begins with a transition from wakefulness to sleep, known as the light sleep phase, followed by the restorative deep sleep phase, essential for physical recovery and growth. The cycle concludes with the Rapid Eye Movement (REM) phase, characterized by high brain activity and vivid dreaming. Insomnia, a prevalent sleep disorder, involves difficulty falling asleep, staying...
01:25Antidepressant Drugs: Overview
Antidepressant drugs are a class of medications primarily used for treating various mood disorders, including major depression, anxiety disorders, and other related conditions. These medicines work by modulating the neurotransmitter balance within the brain, alleviating depressive symptoms. Antidepressants can be broadly categorized into several groups according to their mechanism of action and chemical structure: Selective Serotonin Reuptake Inhibitors (SSRIs), Serotonin-Norepinephrine...
01:28Antidepressant Drugs: Tricyclics, SSRIs, and SNRIs
Tricyclic Antidepressants (TCAs), including Desipramine (Norpramin), Imipramine (Tofranil), Clomipramine (Anafranil), and Amitriptyline (Elavil), inhibit serotonin and norepinephrine reuptake and also block other receptors. They are used for depression, pain conditions, and insomnia. Common adverse effects include anticholinergic effects, sedation, orthostatic hypotension, and weight gain. They have a narrow therapeutic window and so require plasma-level monitoring. Abrupt discontinuation can...
01:21Antipsychotic Drugs: Typical and Atypical Agents
Antipsychotic drugs are classified into first-generation (typical) drugs including phenothiazines; and second-generation (atypical) drugs. Chlorpromazine hydrochloride (Thorazine), a phenothiazine derivative, broadly impacts the central, autonomic, and endocrine systems. This drug, along with typical agents like haloperidol (Haldol), primarily works by antagonizing D2 receptors, thus reducing dopaminergic neurotransmission. However, typical antipsychotics can cause side effects such as sedation...